BACKGROUND: The microtubule-associated tau protein abnormally phosphorylated at threonine 231 (p-tau231) has been investigated as a potential marker of Alzheimer disease. Levels of cerebrospinal fluid (CSF) p-tau231 vary across patients with Alzheimer disease. We hypothesized that these variations partially reflect differences in the degree of neuronal damage and therefore may be used to predict structural disease progression. OBJECTIVE: To investigate whether CSF p-tau231 levels correlate with rates of hippocampal atrophy as an in vivo marker of regional neuronal loss. DESIGN AND PATIENTS: We measured hippocampal volumes on the basis of serial magnetic resonance image examinations in 22 patients with Alzheimer disease. In addition, we determined CSF p-tau231 levels at baseline. RESULTS: Levels of CSF p-tau231 were significantly correlated with baseline hippocampal volumes (P<.001) and rates of hippocampal atrophy (left hippocampus, P<.001; right hippocampus, P = .02), independent of disease duration and severity. CONCLUSION: These findings suggest that variations in p-tau231 levels may be used to predict progression of brain atrophy in patients with Alzheimer disease.
BACKGROUND: The microtubule-associated tau protein abnormally phosphorylated at threonine 231 (p-tau231) has been investigated as a potential marker of Alzheimer disease. Levels of cerebrospinal fluid (CSF) p-tau231 vary across patients with Alzheimer disease. We hypothesized that these variations partially reflect differences in the degree of neuronal damage and therefore may be used to predict structural disease progression. OBJECTIVE: To investigate whether CSF p-tau231 levels correlate with rates of hippocampal atrophy as an in vivo marker of regional neuronal loss. DESIGN AND PATIENTS: We measured hippocampal volumes on the basis of serial magnetic resonance image examinations in 22 patients with Alzheimer disease. In addition, we determined CSF p-tau231 levels at baseline. RESULTS: Levels of CSF p-tau231 were significantly correlated with baseline hippocampal volumes (P<.001) and rates of hippocampal atrophy (left hippocampus, P<.001; right hippocampus, P = .02), independent of disease duration and severity. CONCLUSION: These findings suggest that variations in p-tau231 levels may be used to predict progression of brain atrophy in patients with Alzheimer disease.
Authors: Liana G Apostolova; Kristy S Hwang; John P Andrawis; Amity E Green; Sona Babakchanian; Jonathan H Morra; Jeffrey L Cummings; Arthur W Toga; John Q Trojanowski; Leslie M Shaw; Clifford R Jack; Ronald C Petersen; Paul S Aisen; William J Jagust; Robert A Koeppe; Chester A Mathis; Michael W Weiner; Paul M Thompson Journal: Neurobiol Aging Date: 2010-06-11 Impact factor: 4.673
Authors: Josephine Barnes; Jonathan W Bartlett; Laura A van de Pol; Clement T Loy; Rachael I Scahill; Chris Frost; Paul Thompson; Nick C Fox Journal: Neurobiol Aging Date: 2008-03-17 Impact factor: 4.673
Authors: Anne M Fagan; Denise Head; Aarti R Shah; Daniel Marcus; Mark Mintun; John C Morris; David M Holtzman Journal: Ann Neurol Date: 2009-02 Impact factor: 10.422
Authors: Nikki H Stricker; Hiroko H Dodge; N Maritza Dowling; S Duke Han; Elena A Erosheva; William J Jagust Journal: Brain Imaging Behav Date: 2012-12 Impact factor: 3.978
Authors: P Vemuri; H J Wiste; S D Weigand; L M Shaw; J Q Trojanowski; M W Weiner; D S Knopman; R C Petersen; C R Jack Journal: Neurology Date: 2009-07-28 Impact factor: 9.910
Authors: Harald Hampel; Yong Shen; Dominic M Walsh; Paul Aisen; Les M Shaw; Henrik Zetterberg; John Q Trojanowski; Kaj Blennow Journal: Exp Neurol Date: 2009-10-06 Impact factor: 5.330
Authors: W J P Henneman; H Vrenken; J Barnes; I C Sluimer; N A Verwey; M A Blankenstein; M Klein; N C Fox; P Scheltens; F Barkhof; W M van der Flier Journal: Neurology Date: 2009-09-22 Impact factor: 9.910
Authors: Anders M Fjell; Kristine B Walhovd; Christine Fennema-Notestine; Linda K McEvoy; Donald J Hagler; Dominic Holland; Kaj Blennow; James B Brewer; Anders M Dale Journal: Cereb Cortex Date: 2010-01-04 Impact factor: 5.357